Sign In
Buy IMMX
$8.32
-0.230 (-2.69%)
At Close: Jul 31, 2026
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
09:15am, Thursday, 11'th Sep 2025
– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far –
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
04:05pm, Monday, 08'th Sep 2025
LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell t
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
09:30am, Monday, 25'th Aug 2025
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell
Immix Biopharma Announces Other Serious Diseases Strategy
12:30pm, Wednesday, 06'th Aug 2025
– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – – On track for first Biologics License Applicati
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
09:36am, Friday, 11'th Jul 2025
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
09:35am, Monday, 07'th Jul 2025
– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 i
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 06'th Jun 2025
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immix Biopharma Attends FDA CEO Forum in Washington DC
09:39am, Friday, 06'th Jun 2025
– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D.
Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
09:05am, Friday, 23'rd May 2025
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule
Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety.
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
04:03pm, Wednesday, 21'st May 2025
– Virtual KOL Event Tuesday, June 3, 2025 3:00pm ET – – Attend the event here: https://lifescievents.com/event/immix-asco – LOS ANGELES, CA, May 21, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, I
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
10:04am, Wednesday, 23'rd Apr 2025
— Oral presentation Tuesday, June 3, 2025 in Chicago — LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a
FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL Amyloidosis RMAT designation potentially streamlines the
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
09:34am, Tuesday, 07'th Jan 2025
LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company develo
